Drug Safety 1996Sep; 15 (3): 200-211

RISK-BENEFIT ASSESSMENT o 114-5916/96/CXXl9-D2oo/S06.oo/0

© Adis Internotio nalUmited. All rights reserved.

ACE Inhibitors and the Kidney

A Risk-Benefit Assessment
Gerjan Navis, Harald J. Faber, Dick de Zeeuw and Paul E. de Jong
Groningen Institute for Drug Studies (GIDS), Division of Nephrology, Department of Internal
Medicine, University Hospital Groningen, Groningen, The Netherlands

Contents
Summary ........ . 200
1. Mechanism of Action of ACE Inhibitors 201
2. Renal Effects of ACE Inhibitors . 202
2.1 Essential Hypertension 202
2.2 Renovascular Hypertension . . 203
2.3 Proteinuria and Nondiabetic Chronic Renal Failure 203
2.4 Diabetic Nephropathy . . . . . . . . 205
2.5 Heart Failure . . . . . . . . . . . . . . 205
2.6 Idiosyncratic Renal Adverse Effects 206
3. Drug Interactions ... . . . . . . . . . . . 206
4. Directions for Use . . . . . . . . . . . . . . 206
5. Comparison with Angiotensin II Receptor Blockers 207
6. Conclusion . . . . . . . . . . . . . . . . . . . . . . . 208

Summary ACE inhibitors effectively reduce systemic vascular resistance in patients with
hypertension, heart failure or chronic renal disease. This antihypertensive effi-
cacy probably accounts for an important part of their long term renoprotective
effects in patients with diabetic and non-diabetic renal disease.
The renal mechanisms underlying the renal adverse effects of ACE inhibitors
- intrarenal efferent vasodilation with a consequent fall in filtration pressure -
are held to be involved in their renoprotective effects as well. The fall in filtration
pressure presumably contributes to the antiproteinuric effect as well as to long
term renoprotection. The former is suggested by the positive correlation between
the fall in filtration fraction and the reduction in proteinuria found during ACE
inhibition. The latter is suggested by the correlation between the (slight) reduction
in glomerular filtration rate at onset of therapy and a more favourable course of
renal function in the long term . Such a fall in filtration rate at the onset of ACE
inhibitor treatment is reversible after withdrawal, and can be considered the trade-
offfor long term renal protection in patients with diabetic and nondiabetic chronic
renal disease.
In conditions in which glomerular filtration is critically dependent on angio-
tensin II-mediated efferent vascular tone (such as a post-stenotic kidney, or patients
with heart failure and severe depletion of circulating volume), ACE inhibition
can induce acute renal failure, which is reversible after withdrawal of the drug.
Systemic and renal haemodynamic effects of ACE inhibition, both beneficial
ACE Inhibitors and the Kidney 201

and adverse, are potentiated by sodium depletion. Consequently, sodium repletion

contributes to the restoration of renal function in patients with ACE inhibitor-induced
acute renal failure. On the other hand, co-treatment with diuretics and sodium
restriction can improve therapeutic efficacy in patients in whom the therapeutic
response of blood pressure or proteinuria is insufficient.
Patients at the greatest risk for renal adverse effects (those with heart failure,
diabetes mellitus and/or chronic renal failure) also can expect the greatest benefit.
Therefore, ACE inhibitors should not be withheld in these patients, but dosages
should be carefully titrated, with monitoring of renal function and serum potas-
sium levels.

Since their introduction as antihypertensives in
the early 1980s, the use of ACE inhibitors has ex-
panded greatly. This expansion is not only attrib-
utable to their antihypertensive efficacy, but also to
the discovery of their beneficial effects in other con-
ditions such as heart failure and proteinuria.
Hypertension and heart failure are common con-
ditions in general practice. A recent survey in The
Netherlands, for instance, showed that 1.25% of in-
dividuals over 55 years of age were receiving long
term ACE inhibitor therapy)l] The increase in prev-
alence of long term use of ACE inhibitors, 285%
over the last 5 years, has been more rapid than for
any other class of drugs.
This widespread use prompts a thorough risk-
benefit assessment, with particular reference to
populations at risk. In this article, we present a risk-
benefit assessment of the renal effects of ACE in-
hibitors, both for patients with renal disease and for
patients treated with ACE inhibitors for other con-
ditions.
The renal risk: benefit ratio is of particular in-
terest. Shortly after the introduction of ACE inhib-
itors as antihypertensive agents, severe renal ad-
verse effects (acute renal failure and proteinuria)
were reported, which may have led to a certain ret-
icence over the use of these drugs in patients with
renal disease over those early yearsP] Of note,
however, ACE inhibitors appear to have reno-
protective properties, to the extent that today they
are used to provide renoprotection in patients with
conditions such as diabetic nephropathy[3] and
nondiabetic proteinuria.l 4 ]
It is an apparent paradox that the mechanisms
underlying ACE inhibitor-induced acute renal fail-
ure most likely account for the reno protective ef-
fects as well. Understanding these mechanisms
will help to tailor therapy, and thus allow the clini-
cian to achieve the most favourable risk: benefit
ratio in individual patients.
1. Mechanism of Action of
ACE Inhibitors
ACE inhibitors interact with the renin-angio-
tensin-aldosterone system (RAAS) by competitively
blocking angiotensin-converting enzyme (ACE),
which forms the effector hormone of the RAAS,
the octapeptide angiotensin II, from the inactive
decapeptide angiotensin I. Reduced formation of
angiotensin II is considered to account for many, if
not all, of the known effects of ACE inhibitors.
Angiotensin II is a potent vasoconstrictor of the
systemic and the renal vascular bed. Consequently,
ACE inhibitors produce systemic and renal vaso-
dilation, resulting in a fall in blood pressure and an
increase in renal blood flow. As renal vasodilation
is mainly located at the efferent arteriole, filtration
pressure is reduced by ACE inhibition. In addition,
angiotensin II induces mesangial cell contraction,
thus reducing the glomerular filtration area;[5,6]
thus, ACE inhibitors increase the surface area
available for filtration. As a consequence of these
actions, the lower filtration pressure does not auto-
matically lead to a reduction in glomerular filtration
rate (GFR), as it is counterbalanced by the simul-
taneous increases in renal blood flow and filtration
area. Accordingly, GFR may increase, remain stable

© Adis International Limited. All rights reserved. Drug Safety 1996 Sep: 15 (3)
202
or decrease, depending on the prevailing condi-
tions in the renal microcirculation and the effects
on blood pressure.
The decrease in filtration pressure is believed to
be involved in the initial antiproteinuric effect of
ACE inhibition, as well as in the occurrence of ACE
inhibitor-induced renal failure in some pathologi-
cal conditions. In situations with a low renal perfu-
sion pressure, such as hypovolaemia, heart failure
or renal artery stenosis, GFR is often critically
dependent on angiotensin II-mediated efferent
arteriolar tone. In such conditions, reduction of ef-
ferent vascular tone by ACE inhibitors can dramat-
ically lower GFR, more so when systemic blood
pressure decreases as well. These effects are poten-
tiated by prior sodium depletionP] Thus, a func-
tional, haemodynamically mediated renal insuffi-
ciency can occur, that is reversible after withdrawal
of the ACE inhibitor.
As angiotensin II induces renal sodium reten-
tion by stimulation of aldosterone and by direct
tubular effects,L8] ACE inhibitors induce natriuresis
and mild potassium retention. L9,IO) The latter is cor-
related with the fall in circulating aldosterone
leveIJ II ] Finally, angiotensin II modulates growth
and proliferation of cell types such as vascular
smooth muscle cells Ll2 ] and mesangial cells.£13]
Therefore, angiotensin II probably contributes to
mesangial cell proliferation and matrix accumula-
tion,LI4] processes that are involved in the develop-
ment of focal segmental glomerulosclerosis, LIS] the
alleged final common pathway of progressive renal
failure . In experimental renal disease, the develop-
ment of glomerulosclerosis is prevented or amelio-
rated by ACE inhibitors. LI6 ,17] The clinical counter-
part of this renoprotection is the favourable effect
on the long term course of renal function loss in
patients with diabetic nephropathy and nondiabetic
proteinuria. Whether, in man, anti proliferative ef-
fects contribute to the renoprotective effects of
ACE inhibitors is as yet unknown.
The enzymatic action of ACE is not limited to
the cleavage of angiotensin I; in addition, ACE
(also denoted kininase II) cleaves a number of en-
dogenous peptides, of which bradykinin is proba-
© Adis International Umited. All rights reserved.
Navis et al.
bly the most important. Thus, ACE inhibitors re-
duce bradykinin degradation. Whether this contrib-
utes to their therapeutic effects on the kidney is still
a matter of debate. LI8 ]
To optimise the risk: benefit ratio of ACE in-
hibitors by tailoring therapy, 2 concepts are impor-
tant. First, the mechanism underlying the class-
related adverse effects of ACE inhibitors on renal
function (efferent vasodilation with a fall in filtra-
tion pressure) is also thought to be involved in the
renoprotective effects of ACE inhibitors. Second,
as the systemic and renal haemodynamic effects of
ACE inhibitors (beneficial and adverse) depend on
RAAS blockade, the prevailing state of activation
of the RAAS is an important determinant of these
effects of ACE inhibitors. Thus, the desired thera-
peutic effects of ACE inhibitors can be potentiated
by inducing sodium depletion, by co-treatment with
diuretics and/or by dietary sodium restriction. LI9 ,20]
This will, however, increase the vulnerability of the
kidney to the abovementioned adverse effects.
Tailoring ACE inhibitor therapy, therefore, not
only entails dosage adjustment, but also control of
sodium status.
2. Renal Effects of ACE Inhibitors
2.1 Essential Hypertension
In patients with essential hypertension, ACE in-
hibitors reduce blood pressure and increase renal
blood flow; GFR usually rises or remains stable. In
the subgroup of patients with essential hypertension
who also have an elevated pretreatment renal vas-
cular tone (either resulting from a state of vasocon-
striction inherent to the hypertension L21 ] or from
moderate dietary sodium restriction[22) both renal
blood flow and GFR increase. In essential hyper-
tension ACE inhibitors induce natriuresis during
both low and liberal sodium intake.£19) As these pa-
tients have normal renal function, the fall in aldo-
sterone level does not elicit hyperkalaemia, except
when ACE inhibitors are combined with other
potassium-sparing drugs. (23 )
ACE inhibitors reduce microalbuminuria in pa-
tients with essential hypertension. L24 ] The prognostic
Drug Safety 1996 Sep; 15 (3)
ACE Inhibitors and the Kidney
significance of microalbuminuria with regard to
long term renal outcome in this population remains
to be established, but the association between micro-
albuminuria and rises in serum creatinine levels[25]
suggests that microalbuminuria may be a marker
of long term renal function loss in this population.
Whether this implies that, in essential hyperten-
sion, ACE inhibitors offer advantages over other
classes of antihypertensives with respect to the
long term course of renal function,[26.27] and overall
morbidity and mortality, is still under investigation.
2.2 Renovascular Hypertension
ACE inhibitors were originally designed to treat
high-renin hypertension, of which renovascular
hypertension is the classical example. Not surpris-
ingly, therefore, ACE inhibitors effectively lower
blood pressure in many patients with renovascular
hypertensionPS] Yet, in some patients ACE inhib-
itors fail to lower blood pressure, probably as a
result of the sequential mechanisms that account
for the high blood pressure in patients with renal
artery stenosis. Renin release initiates the hyper-
tension, but when volume expansion subsequently
becomes an additional perpetuating factor for the
hypertension, blood pressure may respond less
well to ACE inhibitors. Thus, a poor blood pressure
response to ACE inhibitors does not exclude the
presence of renal artery stenosis.l 29 )
The presence of (unrecognised) renal artery ste-
nosis in patients treated with ACE inhibitors is a
matter of concern, considering the renal effects of
ACE inhibitors in renovascular hypertension. In a
post-stenotic kidney, glomerular filtration is often
critically dependent on angiotensin II-mediated
efferent vasoconstriction. Thus, ACE inhibitors
can induce a substantial decrease in GFR in a post-
stenotic kidney,[3o.31] which does not occur with other
antihypertensive agents despite similar effects on
blood pressure.[32] In patients with renal artery ste-
nosis of a solitary kidney (a native kidney[33) or a
renal transplant[34]) or in those with bilateral renal
artery stenosis, this can induce acute renal fail-
ure.[35] However, in the presence of a functionally
normal contralateral kidney, even dramatic reduc-
© Adis International Limited. All rights reserved.
203
tions in GFR in the stenotic kidney can go un-
noticed.
In view of its functional nature, the fall in GFR is
reversible after withdrawal of the ACE inhibitor,
even after prolonged use according to some case re-
ports.[36.37] Nevertheless, irreversible loss of stenotic
kidney function during long term ACE inhibition has
also been reported, attributed to accelerated progres-
sion of the stenosis as such. [3S] Therefore, renal artery
stenosis is considered a contraindication for the use
of ACE inhibitors. In selected patients, however,
when anatomical correction of the stenosis is impos-
sible and when blood pressure fails to respond to
other antihypertensives, a trial with a low dosage of
an ACE inhibitor, preferably conducted with the pa-
tient hospitalised, with daily control of blood pres-
sure and creatinine clearance at the onset of therapy,
can sometimes be justified. .
The renal haemodynamic effects of ACE inhib-
itors in patients with renal artery stenosis provide
the physiological basis for the use of acute ACE
inhibitors to increase the sensitivity of renography
in the detection of renal artery stenosis)39,40] Of
note, experimental evidence indicates that long
term ACE inhibition may not increase the sensitiv-
ity of renography as effectively as acute ACE inhi-
bition.[41) In humans, this issue has not been ade-
quately addressed as yet.
2.3 Proteinuria and Nondiabetic Chronic
Renal Failure
ACE inhibitors effectively reduce proteinuria
by approximately 50%.[4] Sodium balance is an im-
portant determinant of the antiproteinuric efficacy;
the latter is virtually abolished when there is a lib-
eral sodium intake,[20) but is restored by dietary
sodium restriction and/or concomitant use of a di-
uretic.l42 ] Dietary protein restriction also increases
the antiproteinuric effect.l43 ]
2.3. , Antiproteinuric Effect
The antiproteinuric effect of ACE inhibitors ex-
ceeds that of other antihypertensives that have sim-
ilar effects on blood pressure;[4,44,45] therefore, it
cannot be explained solely by the decrease in blood
pressure. The reduction in proteinuria is associated
Drug Sofety 1996 Sep; 15 (3)
204
with an improved lipid profile,[46) which may
favourably affect both cardiovascular and renal
outcomeJ47,48)
The antiproteinuric response at the onset of
treatment is correlated with the magnitude of the
early renal haemodynamic response: a larger de-
crease in GFR is associated with a better anti-
protein uric response. Interestingly, an effective
anti protein uric response at the onset of treatment
predicts a more favourable long term course of re-
nal function.[49,50) This supports the assumption
that proteinuria per se is involved in progressive
loss of renal function[51 J and emphasises the impor-
tance of reducing proteinuria as a therapeutic strat-
egy in preventing progressive renal function loss
in patients with proteinuriaJ52,53) This also implies
that a larger fall in GFR at the onset of treatment is
associated with a more favourable long term course
of renal function. [54) Thus, a haemodynamically
mediated decrease in GFR is the price to be paid
for a reduction in proteinuria and for long term
renoprotection.
Unfortunately, this association can limit the use
of ACE inhibitors as antiproteinuric treatment in
patients with severe renal insufficiency; thus, in
patients with advanced renal failure, institution of
ACE inhibitors requires close monitoring of renal
function.
All in all, ACE inhibitors have become drugs of
choice for the symptomatic treatment of proteinuria.
Antiproteinuric efficacy is augmented by concur-
rent treatment with nonsteroidal anti-inflammatory
drugs (NSAIDs),[55) provided that volume over-
load has been adequately corrected by sodium re-
striction and diuretics. However, as this combina-
tion can considerably depress GFR, renal function
and serum potassium levels should be closely mon-
itored, especially in patients with pre-existing im-
pairment of renal function.
2.3.2 Long Term Renal Protection
Whether ACE inhibitors offer better protection
against long term renal function loss in patients
with nondiabetic renal disease than other, equally
effective, antihypertensives is a much-debated is-
sue. Experimental evidence,[16) as well as a number
© Adis International Limited. All rights reserved.
Navis et al.
of retrospective[56) and randomised prospective
studies[57,58) of ACE inhibitor-based treatment re-
gimens, support this assumption. Other studies,
however, have failed to show an advantage of ACE
inhibitors over other antihypertensivesJ59)
The disparities between the studies may result
from differences in study design, degree of blood
pressure control or patient populations. The pro-
portion of patients with proteinuria, for instance,
may be relevant in achieving a protective effect on
long term renal function in a particular study. In
this respect, our recent observation might be rele-
vant: the long term renal function loss in patients
with renal disease and hypertension treated with
either an ACE inhibitor or a ~-blocker, was more
rapid in patients with a DD-polymorphism for the
ACE gene.[60) This genetic polymorphism was re-
cently found to be associated with increased cardio-
vascular riskJ61) The DD-genotype is associated
with elevated serum and tissue ACE levelsJ62)
Whether this phenotypic abnormality affects the
systemic or the renal response to ACE inhibition,
however, is still unclear.[63,64)
2.3.3 Renal Adverse Effects
A number of renal adverse effects of ACE inhib-
itors has been reported in patients with renal fail-
ure. In most cases, these effects result from the
pharmacological actions of ACE inhibitors, namely,
the decreases in filtration pressure and in aldoste-
rone level. Reversible acute renal failure during
ACE inhibition was reported in patients with poly-
cystic kidney disease[65) as well as in patients with
hypertensive nephrosclerosis,[66) in the absence of
renal artery stenosis.
The impairment of renal function is often re-
lated to symptomatic hypotension, and is revers-
ible after discontinuation of ACE inhibitor therapy
and after sodium repletion. Re-institution of the
ACE inhibitor at a lower dosage is often well tol-
eratedJ66) In this respect, it is relevant that many
ACE inhibitors are excreted by the renal route, and
dosage should be reduced accordingly in patients
with renal failure . In renal transplant recipients,
ACE inhibitors can also induce reversible renal
failure in the absence of renal artery stenosis; it has
Drug Safety 1996 Sep; 15 (3)
ACE Inhibitors and the Kidney
been suggested that impaired glomerular perfusion
pressure, caused by changes in the renal micro-
vasculature by chronic vascular rejection (or cyclo-
sporin therapy), predisposes to GFR impairment
during ACE inhibition in these patients,f67]
In patients with renal failure, an elevated aldo-
sterone level helps to maintain potassium bal-
ance;[6S] ACE inhibitors can elicit hyperkalaemia
in these patients because of the decrease in aldo-
sterone level,[69] particularly in patients with ad-
vanced renal failure or those receiving concurrent
treatment with other potassium-sparing drugs.
2.4 Diabetic Nephropathy
Diabetic nephropathy is a major cause of end-
stage renal failure. The natural history of the dis-
ease is characterised by early microalbuminuria and
hyperfiltration, with overt proteinuria and ongoing
renal function loss as the disease progresses. ACE
inhibitors reduce proteinuria in patients with insulin-
dependent diabetes mellitus (IDDM)[3] and non-
insulin-dependent diabetes mellitus (NIDDM),[70]
and retard the rate of renal function loss,f71 .72] The
reduction in proteinuria is associated with an im-
provement in the lipid profile,[73) a risk factor for
both cardiovascular morbidity and long term renal
function loss,f74)
Blood pressure control is an important prereq-
uisite for renoprotection in patients with diabetic
nephropathy, [75] although whether ACE inhibitors
provide long term renoprotection by their effects
on blood pressure or by specific renal effects,[76.77]
is still a matter of debate. Specific renal effects
could include the reduction in proteinuria, lower-
ing of glomerular pressure,[78] antiproliferative ef-
fects, or a combination of these.
Of note, ACE inhibitors also retard the progres-
sion of microalbuminuria to overt proteinuria[79]
and subsequent renal function loss in normotensive
patients with either IDDM[SO] or NIDDM,fsl] As a
consequence, ACE inhibitors are drugs of choice
for hypertensive as well as normotensive patients
with diabetic nephropathy or microalbuminuria. In
hypertensive patients with NIDDM, ACE inhibi-
tors retard the onset of microalbuminuria. [S2J It has
© Adis International Limited. All rights reserved.
205
been recommended,[S3] therefore, that ACE inhib-
itors should be instituted before microalbuminuria
develops.
Hyporeninaemic hypoaldosteronism, resulting
in an elevation of serum potassium levels, is a rel-
atively frequent condition in patients with diabetic
nephropathy;[S4,S5 J therefore, patients with diabetic
nephropathy are at particular risk of developing
hyperkalaemia during ACE inhibitor therapy,[S6]
especially when renal function is impaired.
2.5 Heart Failure
ACE inhibitors have been convincingly shown
to increase life expectancy in patients with heart
failure,ls7J and are now widely used in this common
condition. Their renal effects can vary greatly, de-
pending on the prior condition of the patient.
ACE inhibitors induce renal vasodilation, and
increase renal blood flow in heart failure patients.[SS]
For instance, it has been calculated that two-thirds
of the rise in cardiac output during ACE inhibitor
therapy is accounted for by the increase in renal
perfusion,fs9J However, ACE inhibitors have been
shown to induce acute renal failure, as a result of
functional renal insufficiency, in approximately
one-third of patients with severe heart failure.[90]
Patients prone to develop acute renal failure are
those taking diuretics, with depletion of the effective
circulating volume, and/or with hyponatraemia[9l J
indicating that prior sodium depletion predisposes
to the development of renal failure in these patients.
Indeed, sodium repletion restores renal function de-
spite continuation of ACE inhibitor therapy.[S9J
Diabetic patients with heart failure tend to be par-
ticularly vulnerable to ACE inhibitor-induced
functional impairment of renal function[S9J when
the abovementioned risk factors are present. This
has been suggested to be caused by potentiation of
diuretic-induced volume depletion secondary to
hypoaldosteronism in these patients.
Although patients with heart failure are at a par-
ticular risk of developing renal insufficiency during
ACE inhibition, the cardiac benefits of ACE inhib-
itors in terms of mortality are substantiaL There-
fore, in patients with an ACE inhibitor-induced
Drug Safety 1996 Sep: 15 (3)
206
deterioration in renal function, ACE inhibitors should
not be withheld if at all possible; instead, after a
short wash-out period and tapering of diuretic ther-
apy, they should be continued at a low dosage, sub-
ject to close monitoring of renal function and electro-
lytes.l 861
2.6 Idiosyncratic Renal Adverse Effects
The aforementioned renal adverse effects of
ACE inhibitors - functional renal impairment and
hyperkalaemia in patients at risk - clearly relate to
the pharmacological interruption of the RAAS and,
therefore, are class-specific. In a small number of
patients, however, idiosyncratic renal parenchymal
disease (with or without proteinuria) has been re-
ported with the use of ACE inhibitors, including
acute tubular necrosis, acute interstitial nephritis
and membranous glomerulopathyJ92-94] However,
the early concerns about captopril-induced protein-
uria and membranous glomerulopathy have sub-
sided, as later experience showed that these effects
were related to dosages that far exceeded those cur-
rently in use.
The spectre of renal and nonrenal adverse ef-
fects of ACE inhibitors has been extensively re-
viewed. 195 ] In fact ACE inhibitors generally appear
to be a safe class of drugs, with few renal adverse
effects apart from those explained by the pharma-
cology of these drugs and discussed extensively in
the preceding sections.
3. Drug Interactions
Patients who are treated with ACE inhibitors for
heart failure, hypertension, diabetic nephropathy or
renal failure (with or without proteinuria) seldom
receive mono therapy. In the survey cited in the in-
troduction,l!] the most frequent combinations were
with diuretics (53%), cardiac glycosides (20%), cal-
cium antagonists (20%) or oral anticoagulants
(20%), while 11 % of patients used an NSAID long
term.
The pharmacokinetic interactions of ACE inhib-
itors with other classes of drugs have been exten-
sively reviewed elsewhereJ96] The most important
pharmacodynamic interaction is doubtless that with
© Adis International limited All rights reserved .
Navis et al.
diuretics, not only from a pharmaco-epidemiological
point of view, but because of the potentiation of the
systemic and renal haemodynamic effects of ACE
inhibitors (see section I). This potentiation in fact
can be used as a tool to increase therapeutic effi-
cacy in individual patients with hypertension, pro-
teinuria or heart failure . On the other hand, this
potentiation can elicit renal insufficiency in vulner-
able patients. Combination with potassium-sparing
diuretics is to be avoided because of the high risk
of hyperkalaemia.
The combined use of ACE inhibitors and NSAIDs
also deserves consideration. In patients with pro-
teinuria, this combination can be deliberately used
to improve antiproteinuric efficacy, provided that
therapy is closely monitored (section 2.3.1). In
general practice, however, the combined used of
ACE inhibitors and NSAIDs is often coincidental
rather than deliberate. As NSAIDs induce renal so-
dium retention,[97] they can impair the efficacy of
ACE inhibitors in treating hypertension f98 ] as well
as heart failure. 1991 Therefore, concern should be
raised by a recent epidemiological analysis of ad-
missions for heart failure, which showed a clear-
cut over-representation of patients recently started
on NSAID therapy.lIOO]
4. Directions for Use
As stated above, ACE inhibitors are generally a
well-tolerated class of drugs that elicit few adverse
effects. Optimising the risk: benefit ratio for ACE
inhibitors requires identification of patients who
are at risk of developing renal function deteriora-
tion and/or hyperkalaemia during therapy relative
to the expected benefits of ACE inhibitors in those
patients; this must be followed by careful titration
of therapy. In low-risk patients (those with essen-
tial hypertension), renal function deterioration
with ACE inhibitors is only found in the presence
of concomitant moderate to severe volume deple-
tion, which usually results from the overzealous use
of diuretics or intercurrent conditions inducing vol-
ume depletion, such as gastrointestinal infections.
Thus, in these patients, prevention of clinically
Drug Safety 1996 Sep; 15 (3)
ACE Inhibitors and the Kidney 207

important volume depletion should be sufficient to Table I summarises pharmacokinetic properties

prevent renal adverse effects.
Of note, patient categories at the highest risk of
renal adverse reactions are also those in whom the
expected benefit is highest, namely, patients with
heart failure or diabetic nephropathy (or both).
ACE inhibitors should not be withheld in these pa-
tients if at all possible; however, the dosage of the
ACE inhibitor, as well as that of concomitant di-
uretic therapy, should be adjusted to allow these
patients the benefit of ACE inhibition.
In patients with hyperkalaemia during ACE in-
hibitor therapy, dietary potassium restriction may
help to control potassium levels. Nevertheless, if
intercurrent volume depletion occurs, such pa-
tients are at high risk of developing severe hyper-
kalaemia. Therefore, in these patients, serum elec-
trolyte levels and renal function should be closely
monitored.
At present, there is no evidence that any indi-
vidual ACE inhibitor is to be preferred over the
others with regard to efficacy.[IOI] Pharmacokinetic
differences, thus far, constitute the only well-estab-
lished differences between ACE inhibitors. Many
ACE inhibitors are excreted by the kidney and thus
require dosage adjustment when renal function is
impaired.l 102 ]
of several commonly used ACE inhibitors, as well
as the starting dosages for patients with renal func-
tion impairment, as recommended by the manufac-
turers. It should be noted that first-dose hypotension
can occur despite adequate dosage reduction as it
is determined by pre-existing volume status rather
than by the dosage ofthe ACE inhibitor. In patients
at risk for first-dose hypotension, for instance due
to prior diuretic treatment and/or forward failure,
it can be useful to choose a short-acting ACE in-
hibitor (such as captopril) for a start, to limit the
duration of hypotension, should it occur. If this
ACE inhibitor is well tolerated, it can be safely
replaced by a longer acting one, if desired. After the
initiation of treatment, further up- or down-titration
should occur, guided by blood pressure and renal
function.
5. Comparison with Angiotensin II
Receptor Blockers
ACE inhibitors were the first class of drugs to
effectively block the RAAS. However, angiotensin
II receptor (subtype AT l ) antagonists are now avail-
able as an alternative strategy to eliminate the ef-
fects of angiotensin II.

Table I. Pharmacokinetic properties of ACE inhibitors and recommended starting dosages in patients with impaired renal function
Drug Prodrug Route of tmax t1/2B Recommended starting dose (mg) in renal patients
elimination (h) (h) according to creatinine clearance
<10 ml/min 10-30 ml/min 30-60 ml/min
Benazepril Yes Renal/hepatic 1.5 21 2.5 twice weekly 2.5-5 5-10
Captopril No Renal 1 2 6.25 12.5 12.5 bid
Cilazapril Yes Renal 4 40 0.25-0.5 once or 0.5 1
twice weekly
Enalapril Yes Renal 4 11 2.5 twice weekly 2.5 5
Fosinopril Yes Hepatic/renal 3 12 10 10 10
Lisinopril No Renal 7 13 2.5 twice weekly 2.5-5 5-10
Perindopril Yes Renal 4 25-30 2 twice weekly 2 every 2 days 2
Quinapril Yes Renal 2 3 ? 2.5-5 5-10
Ramipril Yes Renal/hepatic 3 12 ? 1.25 1.25-2.5
Spirapril Yes Renal/hepatic 2.5 30 ? 3 3
Trandolapril Yes Hepatic/renal 4 16-24 0.5 0.5 2
a Except when otherwise indicated, the dose frequency for the recommended starting dosages is once daily.
Abbreviations and symbols: bid = twice daily; t1/2B = terminal elimination half-life (for prodrugs: terminal half-life of active metabolite); t max =
time to peak plasma concentration; ? = dosage not known.

© Adis International Limited. All rights reserved. Drug Safety 1996 Sep: 15 (3)
208
Animal data suggest that some of the renal ac-
tions of ACE inhibitors and AT I receptor antago-
nists may differ. First, renal function impairment in
renovascular hypertension may be less severe with
angiotensin II receptor antagonists than with ACE
inhibitors, suggesting a role for decreased brady-
kinin degradation in functional renal insufficiency
after ACE inhibitionJI03] In rats, the renoprotective
effects of ATI receptor antagonists and ACE inhib-
itors were similar in the renal failure models of
subtotal nephrectomy,[I04] and streptozocin-induced
diabetic nephropathy,[IOS] but ACE inhibition was
claimed to provide better renoprotection in other
renal failure models, namely, puromycin animo-
glycoside (PAN) nephrosis[I06] and early passive
Heymann nephritisJI07] Thus, in experimental re-
nal disease, ACE inhibitors and AT I receptor antag-
onists may have a somewhat different profile with
regard to beneficial as well as adverse renal effects.
In humans, however, the renal effects of AT I
receptor antagonists and ACE inhibitors reported
thus far are more or less similar with respect to
short term renal haemodynamic effects and reduc-
tion of proteinuria, supporting the assumption that
the renal effects of ACE inhibitors are mainly me-
diated by RAAS blockadeJI08,I09] For the moment,
it would be cautious to assume that pharmacologi-
cal renal adverse effects of ATI receptor antago-
nists will be more or less similar to those of ACE
inhibitors.
It should be noted, however, that data on long
term effects of ATI receptor antagonists in man are
lacking thus far. ACE inhibitors and ATI receptor
antagonists exert different effects on several com-
ponents of the RAAS that may be relevant to long
term outcome. AT 1 receptor antagonists, for instance,
induce a pronounced rise in angiotensin II, leaving
the AT 2 receptor subtype exposed to the high angio-
tensin II level. The AT 2 receptor subtype is in-
volved in processes of tissue growth and prolifer-
ation,[lIO] and its role in pathophysiology and in the
effects of ACE inhibition is just on the verge of
being explored. Such differences preclude extrap-
olation of data on long term benefits of ACE inhib-
itors to those of AT 1 receptor antagonists.
© Adis International Limited. All rights reserved.
Navis et al.
6. Conclusion
The perception of the renal risk-benefit ratio of
ACE inhibitors has undergone a remarkable change
since the introduction of these agents. Early studies
focused on the renal risks of ACE inhibition, but
also provided insights into the (patho-) physiology
of the RAAS. This knowledge has contributed to
the success of subsequent studies delineating the
beneficial effects of ACE inhibitors in cardiac and
in renal disease. Whereas reversible renal function
impairment can occur due to ACE inhibition, the
patients at the highest risk for renal adverse effects
(i.e patients with heart failure, diabetes mellitus
and/or chronic renal failure) are also the ones that
can expect the greatest benefit of ACE inhibition.
Therefore, ACE inhibitors should not be withheld
in these patients, but treatment should be carefully
titrated, considering dosage, volume status and the
responses of blood pressure and renal function.
This allows minimisation of the risks of treatment,
and thus to favourably affect the risk-benefit ratio
for the individual patient.
Acknowledgements
GIDS is part of the research school Groningen Utrecht
Institute for Drug Exploration.
References
I. Heerdink ER, Leufkens HG, Glerum JH, et al. Polypharmacy
in the elderly: clustering of drug use. In: Clustering of drug
use in the elderly [thesis]. University of Utrecht: 1995; 65-80
2. Captopril: benefits and risks in severe hypertension [editorial].
Lancet 1980; II: 129-30
3. Parving H-H, Hommel E, Smidt UM. Protection of kidney func-
tion and decrease in albuminuria by captopril in insulin-de-
pendent diabetics with nephropathy. BMJ 1988; 297: 1086-91
4. Heeg JE, de Jong PE, van der Hem, et al. Reduction of protein-
uria by angiotensin converting enzyme inhibition. Kidney Int
1987; 32: 78-83
5. Raij L, Keane WF. Glomerular mesangium: its function and
relationship to angiotensin 11. Am J Med 1985; 79 Suppl. 3c:
24-30
6. Schor N, Ichikawa I, Brenner BM. Mechanism of action of
various hormones and vasoactive substances on glomerular
ultrafiltration in the rat. Kidney Int 1981; 20: 442-51
7. Hricik DE. Captopril-induced renal insufficiency and the role
of sodium balance. Ann Intern Med 1985; 103: 222-3
8. Schuster V. Effect of angiotensin on proximal tubular reabsorp-
tion. Fed Proc 1986; 45: 1444-7
9. Hollenberg NK, Swartz SL, Passan DR. Increased glomerular
filtration rate after converting enzyme inhibition in essential
hypertension. N Engl J Med 1979; 29: 9-12
Drug Safety 1996 Sep: 15 (3)
ACE Inhibitors and the Kidney
10. Atlas SA, Case DB, Sealey JE, et al. Interruption of the renin-
angiotensin system in hypertensive patients by captopril in-
duces sustained reduction in aldosterone secretion, potassium
retention and natriuresis. Hypertension 1979; I: 274-80
II . Tarazi RC, Bravo EL, Fouad FM, et al. Hemodynamic and vol-
ume changes associated with captopril. Hypertension 1980; 2:
576-85
12. Berk BC, Vekshtein V, Gordon HM, et al. Angiotensin 11-
stimulated protein synthesis in cultured vascular smooth mus-
cle cells. Hypertension 1989; 13: 305-14
13. Wolthuis A, Boes A, Rodemann HP, et al. Vasoactive agents
affect growth and protein synthesis of cultured mesangial
cells. Kidney Int 1992; 41 : 124-31
14. Kagami S, Border WA, Mi\1er DE, et al. Angiotensin II stimu-
lates extracellular matrix protein synthesis through induction
of transforming growth factor-beta expression in rat glomer-
ular mesangial cells. J Clin Invest 1994: 93: 2431-7
15. Grond J, Elema JD. Glomerular mesangium: analysis of the
increased activity observed in experimental acute amino-
nucleoside nephrosis in the rat. Lab Invest 1981; 45; 400-9
16. Anderson SA , Rennke HG, Brenner BM. Therapeutic advan-
tage of converting enzyme inhibition in arresting progressive
renal disease associated with systemic hypertension in the rat.
J Clin Invest 1986; 77: 1993-2000
17. Wapstra FH, van Goor H, Navis GJ, et al. The anti protein uric
effect predicts renal protection by ACE-inhibition in rats with
established adriamycin nephrosis. Clin Sci 1996; 90: 393-40 I
18. Johnston CI, Burrell LM. Evolution of blockade of the renin
angiotensin system. J Hum Hypertens 1995; 9: 375-80
19. Navis GJ, de Jong PE, Donker AJM, et al. Diuretic effects of
ACE-inhibition: comparison of low and liberal sodium diet in
hypertensive patients. J Cardiovasc Pharmacol1987; 9: 743-8
20. Heeg JE, de Jong PE, van der Hem GK, et al. Efficacy and
variability of the antiproteinuric effect of ACE inhibition by
lisinopril. Kidney Int 1989; 36: 272-9
21. Hollenberg NK, Meggs LG, Williams GH, et al. Sodium intake
and renal responses to captopril in normal man and in essen-
tial hypertension. Kidney Int 1981 ; 20: 240-5
22. Navis GJ, de Jong PE, Donker AJM, et al. Moderate sodium
restriction in hypertensive subjects: renal effects of ACE-in-
hibition. Kidney Int 1987; 31: 815-9
23. Veterans Administration Cooperative Study Group on Antihy-
pertensive Agents. Low dose captopril for the treatment of
mild to moderate hypertension. Arch Intern Med 1984; 144:
1947-53
24. Ruilope LM, Lahera V, Alcazar JM, et al. Randomly allocated
study of the effects of standard therapy versus ACE inhibition
on micro-albuminuria in essential hypertension. J Hypertens
1994; 12 (4) Supp\.: 59S-63S
25. Madhaven S, Stockwell D, Cohen H, et al. Renal function dur-
ing antihypertensive treatment. Lancet 1995; 345: 749-51
26. Himmelmann A, Hansson L, Hanson B-G, et al. ACE-inhibition
preserves renal function better than beta-blockade in the treat-
ment of essential hypertension. Blood Press 1995 ; 4: 85-90
27. Himmelmann A, Hansson L, Hansson B-G, et al. Superior renal
preservation with an ACE-inhibitor in essential hypertension:
a transient effect? [abstract] Proceedings of the 7th European
Meeting on Hypertension; 1995 June 9-12; Milan, 81
28. Bravo EL, Tarazi RC. Efficacy of an orally active converting
enzyme inhibitor (SQ 14,225) in the treatment of renovascular
hypertension (RVH) in man . Kidney Int 1977; 12: 497-50
29. Derkx FHM, Tan-Tjiong HL, Wenting GJ. Captopril test for
diagnosis of renovascular hypertension. In: Glorioso N, Laragh
© Adis International Limited. All rights reserved.
209
JH, Rapelli A, editors. Renovascular hypertension. New
York : Raven Press, 1986: 70-5
30. Wenting GJ, Derkx FH, Tan-Tjiong LH, et al. Risks of angio-
tensin converting enzyme inhibition in renal artery stenosis.
Kidney Int 1987; 31 Suppl. 20: 180S-183S
31. Textor SC, Tarazi RC, Novick AC, et al. Regulation of renal
hemodynamics and glomerular filtration in patients with re-
novascular hypertension during converting enzyme inhibi-
tion with captopril. Am J Med 1984; 76: 29-37
32. Ribstein J, Mourad G, Mimran A. Contrasting acute effects of
captopril and nifedipine on renal function in renovascular
hypertension. Am J Hypertens 1988; I: 239-44
33. Silas JH, Klenka A, Solomon SA. Captopril-induced reversible
renal failure: a marker of renal artery stenosis affecting a solitary
kidney. BMJ 1983; 286: 1702-3
34. van der Woude FJ, van Son W, Tegzess AM, et al. Effect of
captopril on blood pressure and renal function in patients with
transplant renal artery stenosis. Nephron 1985; 39: 184-8
35. Hricik DE, Browning PJ , Kopelman R, et al. Captopril-induced
functional renal insufficiency in patients with bilateral renal-
artery stenosis or renal artery stenosis in a single kidney. N
Engl J Med 1983; 308: 373-6
36. Durand D, Van Tran T, Ader JL. L'insufficance renale apres
administration de captopril dans les stenoses de I' artere renale
sur rein unique ou les stenoses bilaterales n'est pas obliga-
toire. Arch Mal Coeur 1984; II: 1272-7
37. Salahudeen AK. Pingle A. Reversibility of captopril-induced
renal insufficiency after prolonged use in an unusual case of
renovascular hypertension. J Hum Hypertens 1988; 2: 57
38. Hoefnagels WHL, Thien T. Renal artery occlusion in patients
with renovascular hypertension treated with captopril. BMJ
1986: 292: 24-5
39. Kremer Hovinga TK, de Jong PE, Piers DA, et al. Diagnostic
use of angiotensin converting enzyme inhibitors in radioiso-
tope evaluation of unilateral renal artery stenosis. J Nucl Med
1989; 30: 605-14
40. Fommei E, Ghione S, Palla L, et al. Renal scintigraphic capto-
pril test in the diagnosis of renovascular hypertension. Hyper-
tension 1987; 10: 212-20
41. Visscher CA, de Zeeuw D, Huisman RM . Effect of chronic
ACE-inhibition on the diagnostic value of renography for re-
novascular hypertension ; a preliminary report. Nephrol Dial
Transplant 1995; 10: 263-5
42. Buter H, Hemmelder MH, de Zeeuw D, et al. Hydrochlorothia-
zide potentiates the antiproteinuric efficacy of ACE-inhibition
in patients with non-diabetic renal disease. In press
43. Gansevoort RT, de Zeeuw D, de Jong PE. Additive antiproteinuric
effect of ACE inhibition and a low-protein diet in human renal
disease. Nephrol Dial Transplant 1995; 10: 497-504
44. Apperloo AJ, de Zeeuw D, Sluiter HE, et al. Differential effects
of enalapril and atenolol on proteinuria and renal haemo-
dynamics in non-diabetic renal disease. BMJ 1991; 303: 821-4
45. Gansevoort RT, Sluiter WJ, Hemme1der MH, et al. The anti-
proteinuric effect of blood pressure lowering agents: a meta-
analysis of comparative trials. Nephrol Dial Transplant 1995;
10: 1963-74
46. Gansevoort RT, Heeg JE, Dikkeschei FD, et al. Symptomatic
antiproteinuric treatment decreases serum lipoprotein (a) con-
centration in patients with glomerular proteinuria. Nephrol
Dial Transplant 1994; 9: 244-50
47. Rabelink AJ, Hene R, Erkelens DW, et al. Partial remission of
nephrotic syndrome in patients on long-term simvastatin.
Lancet 1990; 335: 1045-6
Drug Safety 1996 Sep: 15 (3)
210
48. Keane WF, Kasiske BL, O'Donnell MP. Hyperlipidemia and the
progression of chronic renal disease. Am J Clin Nutr 1988;
47: 157-60
49. Apperloo AJ, Zeeuw D de, de Jong PE. Short-term antiprotein-
uric response to antihypertensive treatment predicts long-
term GFR decline in patients with non-diabetic renal disease .
Kidney Int 1994; 45 Suppl.: 174S-178S
50. Gansevoort RT, de Zeeuw D, de Jong PE. Long-term benefits of
the anti-proteinuric effect of ACE-inhibition in non-diabetic
renal disease. Am J Kidney Dis 1993; 2: 202-6
51. Remuzzi G, Bertani T. Is glomerulosclerosis a consequence of
altered glomerular permeability to macromolecules? Kidney
Int 1990;38: 384-94
52. de Jong PE, Anderson S, de Zeeuw D. Glomerular preload and
afterload reduction as a tool to lower urinary protein leakage:
will such treatments also help to improve renal function out-
come? J Am Soc Nephro11993; 3: 1333-41
53. de Jong PE, Heeg JE, Apperloo AJ, et al. The antiproteinuric
effect of blood-pressure lowering agents: differences between
diabetics and non-diabetics. J Cardiovasc Pharmacol 1992;
19: Suppl.6: 28S-32S
54. Apperloo AJ, de Zeeuw D, de Jong PE. A short-term antihyper-
tensive treatment-induced fall in glomerular filtration rate
reflects long-term renal progression. Kidney Int 1994: 45; 174-8
55. Heeg JE, de Jong PE, Vriesendorp R, et al. Additive anti-
proteinuric effect of the NSAID indomethacin and the ACE
inhibitor Iisinopril. Am J Nephrol 1990; 10 Suppl. I: 94-7
56. Mann JFE, Resich C, Ritz E. Use of angiotensin-converting
enzyme inhibitors for the preservation of kidney function: a
retrospective study. Nephron 1990; 55 Suppl.: 38-42
57. Kamper A-L, Strandgaard S, Leyssac PP. Late outcome of a
controlled trial of enalapril treatment in progressive chronic
renal failure : hard end-points and influence of proteinuria.
Nephrol Dial Transplant 1995; 10: 1182-88
58. Hannedouche T, Landais P, Goldfarb B, et al. Randomised con-
trolled trial of enalapril and beta-blockers in non-diabetic
chronic renal failure. BMJ 1994; 309: 833-7
59. Zucchelli P, Zuccala A, Gaggi R. Comparison of the effects of
ACE-inhibitors and calcium channel blockers on the progres-
sion of renal failure . Nephrol Dial Transplant 1995; 10 Suppl.
9: 46-51
60. van Essen GG, Rensma PL, de Zeeuw D, et al. Association
between angiotensin-converting-enzyme gene polymorphism
and failure of reno protective therapy. Lancet 1996; 347: 94-5
61. Cambien F, Poirier 0, Lecerf L, et al. Deletion polymorphism
in the gene for angiotensin-converting enzyme is a potent risk
factor for myocardial infarction. Nature 1992; 359: 641-4
62. Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion
polymorphism in the angiotensin-I converting enzyme gene
accounting for half of the variance in serum enzyme levels. J
Clin Invest 1990; 86: 1343-6
63. Yoshida H, Mitarai T, Kawamura T, et al. Role of the deletion
polymorphism of the angiotensin converting enzyme gene in
the progression and therapeutic responsiveness of IgA ne-
phropathy. J Clin Invest 1995; 96: 2162-9
64. van der Kleij FHG, Navis GJ, Scheffer H, et al. ACE genotype
does not determine short-term renal response to ACE inhibi-
tion in proteinuric patients. Nephrol Dial Transplant. In press
65. Chapman AB, Gabow PA, Schrier RW. Reversible renal failure
associated with angiotensin-converting enzyme inhibitors in
polycystic kidney disease. Ann Intern Med 1991; 115: 769-73
66. Toto RD, Mitchell HC, Lee H-C, et al. Reversible renal failure
due to angiotensin converting enzyme inhibitors in hyper-
tensive nephrosclerosis. Ann Intern Med 1991; 115: 513-9
© Adis International limited. All rights reserved.
Navis et al.
67 . Nath KA, Crumbley AJ, Murray BM, et al. Captopril and renal
insufficiency. N Engl J Med 1983; 309: 666
68. Hene RJ, Boer P, Koomans HA, et al. Plasma aldosterone con-
centrations in chronic renal disease. Kidney Int 1092; 21 : 98-10 I
69. Textor SC, Bravo EL, Fouad FM. Hyperkalemia in azotemic
patients during angiotensin-converting enzyme inhibition and
aldosterone reduction with captopril. Am J Med 1982; 73:
719-25
70. Ravid M, Savin H, Jutrin Y, et al. Long-term stabilizing effect
of angiotensin-converting enzyme inhibition on plasma cre-
atinine and on proteinuria in normotensive type II diabetic
patients. Ann Intern Med 1993; 118: 577-81
71. Bjorck S, Nyberg G, Mulec H, et al. Beneficial effects of angio-
tensin converting enzyme inhibition on renal function in pa-
tients with diabetic nephropathy. BMJ 1986; 293: 467-70
72. Bjorck S, Mulec H, Johnsen SA, et al. Renal protective effects
of enalapril in diabetic nephropathy. BMJ 1992; 304: 339-43
73. Ravid M, Neumann L, Lishner M. Plasma lipids and the pro-
gression of nephropathy in diabetes mellitus type II: effects
of ACE-inhibitors. Kidney Int 1995; 47: 907-10
74. Mulec H, Johnson SA, Wiklund 0, et al. Cholesterol as a renal
risk factor in diabetic nephropathy. Am J Kidney Dis 1993;
22: 193-201
75. Parving HH, Andersen AR, Smidt UM, et al. Effect of antihy-
pertensive treatment on kidney function in diabetic nephro-
pathy. BMJ 1987; 294: 1443-7
76. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angio-
tensin converting enzyme inhibition on diabetic nephropathy.
N Engl J Med 1993; 329: 1456-62
77. Kasiske B, Kalil RSN, Ma JZ, et al. Effect of antihypertensive
therapy on the kidney in patients with diabetes: a meta-regression
analysis. Ann Intern Med 1993; 118: 129-38
78. Anderson S, Rennke HG, Garcia DL, et al. Short and long term
effects of antihypertensive therapy in the rat. Kidney Int 1989;
36: 526-36
79. Viberti GC, Mogensen CE, Groop Le, et al. Effect of captopril
on progression to clinical proteinuria in patients with insulin-
dependent diabetes mellitus and microalbuminuria. JAMA
1994; 271: 275-9
80. Mathiesen ER, Hommel E, Giese J, et al. Efficacy of captopril
in postponing nephropathy in normotensive insulin dependent
diabetic patients with microalbuminuria. BMJ 1991; 303: 81-7
81. Ravid M, Lang R, Rachmani R, et al. Long-term renoprotective
effect of angiotensin-converting enzyme inhibition in non-
insulin-dependent diabetes mellitus: a 7-year follow-up. Arch
Intern Med 1996; 156: 286-9
82. Lebovitz HE, Wiegmann TB, Cnaan A, et al. Renal protective
effects of enalapril in hypertensive NIDDM: role of baseline
albuminuria. Kidney Int 1994; 45 Suppl. 45: 150S-55S
83. Mogensen CE, Keane WF, Bennett PH, et al. Prevention of
diabetic renal disease with special reference to micro-
albuminuria. Lancet 1995; 346: 1080-4.
84. Tuck ML, Mayes DM. Mineralocorticoid biosynthesis in pa-
tients with hyporeninemic hypoaldosteronism. J Clin Endo-
crinol Metab 1980; 50: 341-7
85. Schambelan M, Sebastian A, Biglieri EG. Prevalence, patho-
genesis and functional significance of aldosterone deficiency
in hyperkalemic patients with chronic renal insufficiency.
Kidney Int 1980: 17; 89-101
86. Toto RD. Renal insuffiency due to angiotensin-converting en-
zyme inhibitors. Miner Electrolyte Metab 1994; 20: 193-200
87. SOLVD Investigators. Effect of enalapril on survival in patients
with reduced left ventricular ejection fractions and congestive
heart failure . N Engl J Med 1991 ; 325: 293-7
Drug Safety 1996 Sep; 15 (3)
ACE Inhibitors and the Kidney
88. Kubo S, Nishioka A, Nishimura H, et al. Effects of captopril on
arterial and venous pressure, renal function, and humoral fac-
tors in severe chronic congestive heart failure. Clin Pharmacol
Ther 1984; 36: 456-63
89. Gavras I, Gavras H. Captopril and enalapril. Ann Intern Med
1983; 94: 58-9
90. Packer M, Lee WH, Medina N, et al. Functional renal insuffi-
ciency during long-term therapy with captopril and enalapril
in severe chronic heart failure. Ann Intern Med 1987; 106:
346-54
91. Dzau VJ, Hollenberg NK. Renal response to captopril in severe
heart failure: role of furosemide in natriuresis and reversal of
hyponatremia. Ann Intern Med 1984; 100: 777-82
92. Hoorntje SJ, Kallenberg CGM, Weening JJ, et al. Immune-
complex glomerulopathy in patients treated with captopril.
Lancet 1980;1: 1212-4
93. Smith WR, Neill J, Cushman WC, et al. Captopril-associated
acute interstitial nephritis. Am J Nephrol 1989; 9: 230-5
94. Murphy BF, Whitworth JA, Kincaid-Smith P. Renal insuffi-
ciency with combinations of angiotensin converting enzyme
inhibitors and diuretics. BMJ 1984; 288: 844-5
95. DiBianco R. Adverse reactions with angiotensin converting
enzyme (ACE) inhibitors. Medical Toxicol 1986; I: 122-41
96. Shionoiri H. Pharmacokinetic drug interactions with ACE-
inhibitors. Clin Pharmacokinet 1993; 25: 20-58
97. Murray MD, Brater DC. Renal toxicity of the non-steroidal
anti-inflammatory drugs. Annu Rev Toxicol 1993; 435-65
98. Covi G, Minuz P, Capuzzo G, et al. Reduction in the antihyper-
tensive effect of captopril induced by prostaglandin syn-
thetase inhibition. Int J Clin Pharmacol Res 1984; 4: 47-52
99. Dzau VJ, Packer M, Lilly LS, et al. Prostaglandins in severe
heart failure . N Engl J Med 1984; 310: 347-52
100. Heerdink ER, Leufkens HG, Herings RM , et al. NSAIDS in-
crease the risk of congestive heart failure in elderly patients
on diuretics. In press
© Adis International Limited. All rights reserved.
211
lOt. Leonetti G, Cuspidi C. Choosing the right ACE inhibitor: a
guide to selection. Drugs 1995; 49: 516-35
102. Carter BL. Dosing of antihypertensive medications in patients
with renal insufficiency. J Clin Pharmacol1995; 35: 81-6
103. Demeillers B, Jover B, Mimran A. Renal function in one kidney,
one clip sodium-restricted rats: influence of enalapril and
losartan. J Hypertens 1995; 13: 1764-6
104. Kohara K, Mikami H, Okuda N, et al. Angiotensin blockade
and the progression of renal damage in the spontaneously
hypertensive rats. Hypertension 1993; 21: 975-9
105. Anderson S, Jung FF, Ingelfinger JR. Renal renin-angiotensin
system in diabetes: functional, immunohistochemical, and
molecular biological considerations. Am J Physiol 1993; 265:
F477-86
106. Hutchinson FN, Webster SK. Effect of Ang II receptor antago-
nist on albuminuria and renal function in passive Heymann
nephritis. Am J Physiol 1992; 263: F311-F318
107. Tanaka R, Kon V, Yoshioka T, et al. Angiotensin converting
enzyme inhibitor modulates glomerular function and struc-
ture by distinct mechanisms. Kidney Int 1994; 43: 537-42
108. Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric
effect of ACE-inhibition mediated by interference with the
renin-angiotensin system? Kidney Int 1994; 45: 861-7
109. Johnston CI. Angiotensin receptor antagonists: focus on losartan.
Lancet 1995; 346: 1403-7
110. Stoll M, Steckelings UM, Paul M, et al. The angiotensin II AT 2
receptor mediates inhibition of cell proliferation in coronary
endothelial cells. J Clin Invest 1995; 95: 651-7
Correspondence and reprints: Dr Paul E. de long, Depart-
ment of Internal Medicine, University Hospital Groningen,
Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
E-mail: M.J.S.Graler@med.rug.nl
Drug Safety 1996 Sep; 15 (3)